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tolerance: reanalysis of data from the NAVIGATOR
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Abstract
Objective To examine the degree to which use of β blockers, statins,
and diuretics in patients with impaired glucose tolerance and other
cardiovascular risk factors is associated with new onset diabetes.
Design Reanalysis of data from the Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Setting NAVIGATOR trial.
Participants Patients who at baseline (enrolment) were treatment naïve
to β blockers (n=5640), diuretics (n=6346), statins (n=6146), and calcium
channel blockers (n=6294). Use of calcium channel blocker was used
as a metabolically neutral control.
Main outcome measures Development of new onset diabetes
diagnosed by standard plasma glucose level in all participants and
confirmed with glucose tolerance testing within 12 weeks after the
increased glucose value was recorded. The relation between each
treatment and new onset diabetes was evaluated using marginal
structural models for causal inference, to account for time dependent
confounding in treatment assignment.
Results During the median five years of follow-up, β blockers were
started in 915 (16.2%) patients, diuretics in 1316 (20.7%), statins in 1353
(22.0%), and calcium channel blockers in 1171 (18.6%). After adjusting
for baseline characteristics and time varying confounders, diuretics and
statins were both associated with an increased risk of new onset diabetes
(hazard ratio 1.23, 95% confidence interval 1.06 to 1.44, and 1.32, 1.14
to 1.48, respectively), whereas β blockers and calcium channel blockers
were not associated with new onset diabetes (1.10, 0.92 to 1.31, and
0.95, 0.79 to 1.13, respectively).
Correspondence to: H Krum henry.krum@monash.edu
Extra material supplied by the author (see http://www.bmj.com/content/347/bmj.f6745?tab=related#datasupp)
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Conclusions Among people with impaired glucose tolerance and other
cardiovascular risk factors and with serial glucose measurements,
diuretics and statins were associated with an increased risk of new onset
diabetes, whereas the effect of β blockers was non-significant.
Trial registration ClinicalTrials.gov NCT00097786.
Introduction
Use of β blockers, diuretics, and statins has been established to
reduce cardiovascular morbidity and mortality in a variety of
diseases.1 However, although statins reduce cardiovascular
events and mortality in patients with coronary artery disease or
equivalent risk factors,2 debate continues about their role in
primary prevention in lower risk populations.3
Despite the overwhelming benefits of these drugs on
cardiovascular outcomes, recent evidence suggests that long
term use may increase the risk of diabetes. Large trials
examining cardiovascular outcomes and mortalities suggested
an increased incidence of new onset diabetes with long term
use of diuretics.4 5 Likewise, other studies have reported an
increased incidence of diabetes in people treated with statins,3-8
prompting the US Food and Drug Administration to release a
safety label change in 2012.9 Furthermore, β blockers have been
implicated in impaired glucose metabolism, especially with
diuretics.5
Large scale studies with serial glucose measurements examining
the association between these drugs and new onset diabetes in
patients with impaired glucose tolerance are limited. We
reanalysed data from the Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research (NAVIGATOR) study
to examine the relation between risk of new onset diabetes and
use of β blockers, thiazide diuretics, or statins in treatment naïve
patients.
Methods
NAVIGATORwas amultinational, randomised, double blinded,
placebo controlled trial examining the effects of valsartan and
nateglinide on conversion to type 2 diabetes mellitus and
cardiovascular outcomes in patients with impaired glucose
tolerance and other cardiovascular risk factors. The study design
and results have been previously published,10-12 as have the
eligibility criteria (see supplementary appendix).12
Endpoint definitions
The endpoint of interest was diagnosis of new onset diabetes.
We measured fasting plasma glucose every six months for the
first three years of follow-up and then annually. Oral glucose
tolerance tests were performed yearly. New onset diabetes was
defined by a fasting plasma glucose level ≥126 mg/dL (7.0
mmol/L) or a glucose level ≥200 mg/dL (11.1 mmol/L) two
hours after an oral glucose tolerance test, confirmed by an oral
glucose tolerance test within 12 weeks after the increased
glucose value was recorded.We separated the diabetes endpoint
into 12 time windows (every six months for three years and 12
months subsequently).
Drugs
We studied calcium channel blockers as a potential metabolically
“neutral” control and expected that their use would be similar
to that of β blockers, diuretics, and statins and, therefore, would
have a similar potential for unmeasured confounding. However,
calcium channel blocker use should not have any adverse or
beneficial metabolic impact.13As a negative control, to evaluate
our methodology, we also assessed the relation between
receiving a calcium channel blocker and subsequent progression
to new onset diabetes. β blockers, diuretics, statins, and calcium
channel blockers were prescribed to patients in the
NAVIGATOR trial as part of routine clinical care, and recorded
subsequent to randomisation.
Study population
Although many patients were taking cardiovascular therapies
at baseline, this cohort represents a heterogeneous group with
unknown, differential lengths of exposure to treatment and
unknown circumstances preceding treatment initiation. In
addition, patients who developed diabetes, potentially as a
consequence of these drugs, would not be eligible for the study,
leaving a biased sample of patients taking drugs at baseline. To
avoid these biases, we evaluated treatment initiation in a
population that was treatment naïve to each class of drug at
baseline. Thus, of 9306 patients enrolled in NAVIGATOR, four
unique subgroups were identified for evaluating each therapy
(figure⇓): β blockers (n=5640), diuretics (n=6346), statins
(n=6146), and calcium channel blockers (n=6294). In this study,
the median follow-up time for diabetes was five years from
baseline, with a maximum of six years.
Covariate follow-up
We identified potential confounders in the relation between
non-randomised treatments and progression to new onset
diabetes through known clinical risk factors, with additional
input obtained from consensus of the clinical and analytical
team. The reasons for initiating each therapy and variables
known to be highly associated with new onset diabetes were
listed and we mapped these to the corresponding variable in the
NAVIGATOR trial (table 1⇓). Given that the population was
treatment naïve at baseline, post-baseline information on these
covariates was possibly informative. Updated values for time
dependent confounders were available according to the visit
schedule in table 1.
Statistical analysis
Among the treatment naïve populations, we compared baseline
characteristics between those who did and did not receive
treatment. We summarised continuous characteristics using the
median (25th, 75th centile) and compared them using the
Student’s t test; categorical variables were summarised with
frequency and percentage and compared using the Pearson χ2
or Fisher exact test.
To evaluate the effect of the drugs on progression to diabetes,
we constructed four marginal structural models,14 one for each
drug. Unlike traditional methods, this approach can account for
treatment selection bias that may depend on baseline and time
dependent variables.15 The marginal structural model closely
resembles a Coxmodel, with baseline covariate adjustment and
treatment included as a time dependent covariate. Specifically,
the treatment of interest was assigned the value 0 during periods
in which treatment was withheld and 1 when treatment was
used, potentially reflecting starting, stopping, and subsequent
changes. The distinguishing feature of the marginal structural
model is that inverse probability of treatment weighting is
applied to account for time dependent variables that may be
associated with initiating or discontinuing treatment. The
propensity to receive treatment is recalculated according to new
information at each time interval, and the weights are
correspondingly updated. Under the assumption of no
unmeasured confounders, baseline or time varying, the observed
treatment patterns become pseudorandomised. The resemblance
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to the Cox model allows estimation of a hazard ratio, with the
usual proportional hazards interpretation. We used the Breslow
method to handle tied events times (because diabetes was
measured only at six or 12 month intervals), which facilitated
the use of weights. We censored the follow-up for diabetes at
six years, beyond which the data were too sparse to adequately
adjust for confounding.
In the model we included as covariates those baseline variables
that were previously identified as significantly associated with
new onset diabetes in the NAVIGATOR trial. Wemodelled the
propensity to receive treatment at each time window as a
function of all time dependent covariates listed in table 1,
updated to their value at the previous timewindow. The rationale
was that these treatments are often used in conjunction and that
known reasons for initiation of one treatment may be associated
with the use of other treatments, regardless of a direct impact.
Moreover, we adjusted for time dependent measures of fasting
glucose and oral glucose tolerance. This adjustment allowed us
to balance patients according to precursor measurements of the
endpoint itself. To account for selective loss to follow-up, we
similarly modelled the propensity to be censored. At each time
point, we calculated stabilised weights using inverse probability
of treatment and inverse probability of censoring.14 We fit all
continuous variables using a flexible spline to account for
possible non-linearity. Approximately 20% of patients were
missing a variable of interest at baseline (primarily glycated
haemoglobin, HbA1c). Baseline missing data were multiply
imputed, and final estimates (and associated standard errors)
reflect the combined analysis over five imputed datasets. We
measured time dependent variables with varying frequency and
additionally exhibitedmissing data. For time dependent variables
we used a last value carried forward approach, within each
imputation. We think this is reasonable as it captures the most
recent available information for decision making. The
measurement schedule is included in the supplementary file.
As with inverse probability of treatment weighting, it is
important to assess andminimise the impact of extremeweights,
by which a few patients who are unlikely to receive treatment
could exert undue influence on the results. Previous investigators
recommend conducting a series of sensitivity analyses,
successively truncating the weights to evaluate variation in the
results.16 Extreme weights were rare within the six year
follow-up period. We report the primary results based on
minimal truncation of weights at the 0.25 and 99.75 centiles.
Alternative truncation strategies did not change the results and
are reported in the supplementary file.
As with a time dependent Cox model, the primary result of the
marginal structural model is a hazard ratio for treatment. To
improve clinical interpretability, we sought to illustrate the
discrepancy in event rates implied by the observed hazard. We
used the marginal structural model to derive adjusted, five year
event probabilities for two hypothetical trajectories of the time
dependent covariate: no treatment throughout follow-up, or
constant treatment throughout follow-up. Specifically, we used
the Breslow estimator (1 minus the exponential of the negative
empirical cumulative hazard estimate), fixing the level of
treatment (0 and 1) and balancing other covariates by weighting
(that is, fitting the marginal structural model). This estimation
corresponds to the standard calculations for a Cox model, with
the addition of weights. The absolute excess risk at five years
was calculated as the difference between five year event
probabilities, and its inverse was the number needed to harm.
Confidence intervals for number needed to harmwere calculated
according to the Altman method.17
As a point of comparison, we also fit the standard Cox
proportional hazard model including the treatment of interest
as a time dependent covariate, initially unadjusted and then
adjusted only for baseline characteristics. This model cannot
account for the changes in patients’ characteristics that led to
treatment decisions and therefore is likely to be biased.
Results
Among the 9306 participants enrolled in the NAVIGATOR
trial, 915 (16.2%) of 5640 who were β blocker naïve at baseline
started β blocker treatment during follow-up, 1316 (20.7%) of
6346 who were diuretic naïve started diuretic treatment, 1353
(22.0%) of 6146 who were statin naïve started statin treatment,
and 1171 (18.6%) of 6294 who were calcium channel blocker
naïve started calcium channel blocker treatment. In treatment
naïve patients, those who started treatment had baseline fasting
blood glucose and HbA1c levels similar to those in patients who
never started on any of the four therapies. Compared with
patients who did not start treatment, patients who did start any
of the four therapies were older and more likely to have
hypertension, congestive heart failure, a history of coronary
artery bypass graft surgery, angina, or other major cardiovascular
events. Among the four treatment naïve groups, baseline values
for blood pressure, weight, sex, and albumin/creatinine ratios
were similar to those in patients who started therapy (table 2⇓).
Frequency of concomitant drug use was similar across the
therapies of interest. For example, statins were used in 40%,
39%, and 40% among patients taking β blockers, diuretics, and
calcium channel blockers at one year, respectively. The results
were similar for other pairings, and across time (see
supplementary file for details).
Incidence of new onset diabetes
After adjusting for baseline characteristics and time varying
covariates, patients receiving diuretics and statins had
significantly higher rates of new onset diabetes compared with
patients not starting treatment (table 3⇓). Themarginal structural
model adjusted hazard ratio for new onset diabetes in patients
treated with diuretics compared with those who were not was
1.23 (95% confidence interval 1.06 to 1.44); the number needed
to harm was 17 (95% confidence interval 9 to 68). Likewise,
the marginal structural model hazard ratio for new onset diabetes
in the statin treated group, compared with the non-treated group,
was 1.32 (1.14 to 1.48); the number needed to harm was 12 (8
to 29). For the β blockers group, the risk of new onset diabetes
was numerically higher but non-significant (marginal structural
model hazard ratio 1.10, 0.92 to 1.31). No association was found
between calcium channel blocker use and development of new
onset diabetes (marginal structural model hazard ratio 0.95, 0.79
to 1.13). The results remained stable in sensitivity analyses
involving different truncations of weights. Table 3 displays the
results from unadjusted and baseline adjusted Cox proportional
hazard models.
Discussion
After adjustment for baseline and time varying confounders,
diuretic use and statin use were significantly associated with
new onset diabetes. For β blockers, a non-significant difference
in the development of new onset diabetes was observed. Our
findings provide further evidence that in high risk people with
impaired glucose tolerance, use of diuretics and statins may be
associated with an increased risk of new onset diabetes.
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Before studying the effect of each drug on development of new
onset diabetes, we first examined the concomitant use of those
drugs in the NAVIGATOR (Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes Research) trial. We
found that in this high risk population, as expected, statins were
used as a concomitant therapy with β blockers as often as with
diuretics and calcium channel blockers. Although we did not
analyse drug-drug and drug-disease interactions, by accounting
for concomitant treatment usage, we limited the confounding
of multiple drugs on new onset diabetes. Given this
methodology, our study further supports the independent effect
of statins on new onset diabetes and emphasises the substantial
net effect in a high risk population with impaired glucose
tolerance.
In the past decade, studies have found varying associations
between diabetes risk and use of β blockers, diuretics, and
statins.18 19 Compared with previous studies using investigator
reported or patient reported data on new onset diabetes or
administrative claims, theNAVIGATOR trial used serial glucose
measurements that enhanced detection of risk for new onset
diabetes in a high risk population with impaired glucose
tolerance.We found that the increased risk of new onset diabetes
associated with diuretic use was similar to that of previous
studies.20 Some observational studies have shown a 20% to 40%
increased risk of developing new onset diabetes in patients
taking compared with not taking diuretics,13 21 whereas other
studies have shown similar risks of development for new onset
diabetes in patients treated with diuretics compared with
angiotensin converting enzyme inhibitors.22
In several major antihypertensive studies, among non-diabetic
patients with hypertension, the number needed to harm with
respect to new onset diabetes ranged from 125 to 167 over four
to six years of follow-up.8 In The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial, among
patients with hypertension and a high risk of cardiovascular
disease, the incidence of diabetes at four years was 11.6% for
chlorthalidone and 9.8% for amlodipine (number needed to
harm for chlorthalidone=167 at four years of follow-up).20 For
the Captopril Prevention Project study among hypertensive,
non-diabetic patients, the number needed to harm for diuretic
or β blocker therapy, or both was 125 at six years of follow-up.23
However, the effect of diuretics had not yet been examined in
an impaired glucose tolerance population. In our study, one
additional case of diabetes occurred within five years for every
17 patients treated with diuretics. This lower number needed to
harm can be attributed to our population of patients with
impaired glucose tolerance having a high propensity for new
onset diabetes and serial glucose measurement.
Among patients taking β blockers, previous studies have
reported up to a sixfold increased risk of new onset diabetes.24
In the Losartan Intervention For Endpoint reduction in
hypertension study, among non-diabetic hypertensive patients
with left ventricular hypertrophy, the incidence of diabetes was
6% compared with 8% for patients taking losartan versus
atenolol (adjusted hazard ratio 0.75, 95% confidence interval
0.63 to 0.88).25 In another large prospective trial with new onset
diabetes as a primary endpoint among non-diabetic hypertensive
patients, those taking β blockers compared with not taking β
blockers had a 28% increased risk of developing subsequent
diabetes (adjusted hazard ratio 1.28, 95% confidence interval
1.04 to 1.57).26 The mechanism of β blocker induced new onset
diabetes has been postulated to result from a combination of
changes in lipoprotein lipase activity, attenuation of the release
of insulin by pancreatic β cells, weight gain where increased
adiposity constrains the distribution of insulin, and peripheral
vasoconstriction from unopposed α adrenergic activity.5 In our
analysis, we did not find a statistically significant association
between use of β blockers and new onset diabetes. However,
the estimated hazard ratio of 1.10 and confidence interval (0.92
to 1.31) were not inconsistent with previous studies. Thus, an
important detrimental effect cannot be excluded, and a large
sample size would be required to detect a moderate effect.
Furthermore, the lack of significant association may also be
attributed to the mixed receptor specificity, dosage, and duration
of β blocker treatment in our study, as other studies of β blockers
have yielded varying results based on the categories and dosages
used.27
Initial data linking statin use and diabetes suggested a protective
effect of these drugs. TheWest of Scotland Coronary Prevention
Study reported a 30% reduction in the hazard of developing
diabetes with pravastatin.28 However, more recent studies
examining higher potency statins have suggested a link between
statin potency and risk of new onset diabetes. One study reported
that statin use resulted in a 48% increased risk of new onset
diabetes in postmenopausal women.29 Likewise, results from
the Justification for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER) showed
a 25% higher proportion in investigator reported diabetes in
patients treated with rosuvastatin versus placebo.3 A
meta-analysis of 13 trials involving 91 140 patients showed a
9% increased risk of diabetes among statin treated patients,7
leading the Food and Drug Administration in 2012 to add a
warning label to statin drugs marketed and sold in the United
States.9 The relative effect of statins on new onset diabetes was
similar in our study, with a 32% increased risk of new onset
diabetes in patients receiving statins. Compared with previous
studies, our population with impaired glucose tolerance has a
smaller number needed to harm, with one case of new onset
diabetes for every 12 patients treated over five years; whereas
in a population with non-impaired glucose tolerance, the number
needed to harm has been as high as 255 over four years.7
Although the relative risk was similar, we saw a greater net
impact of statin therapy on new onset diabetes than in previous
studies, in our population of high risk patients with impaired
glucose tolerance.
Another study of patients at high risk of new onset diabetes
included a subgroup of patients from the JUPITER trial, which
examined patients with major risk factors for diabetes, including
metabolic syndrome, impaired fasting glucose, and high body
mass index or HbA1c levels, and showed a hazard ratio for statin
therapy similar to that in our study (1.28, 95% confidence
interval 1.07 to 1.54).8 However, this study had a lower event
rate than in our study (treated versus untreated, 2.12% v 1.65%,
and 41% v 33%, respectively) over a similar follow-up period.
Therefore, we found a much higher net risk towards new onset
diabetes compared with other high risk populations with
diabetes. Again, this difference may be due to the patients with
impaired glucose tolerance in our study being closer to the
threshold for overt new onset diabetes than the patients with
metabolic syndrome from JUPITER, as well as the use of serial
glucose measurements with laboratory confirmation, allowing
for a more accurate and thus higher detection rate of diabetes.
The potential for unmeasured confounding remains a concern
in this observational study. To the extent that these treatments
are used in similar populations, the magnitude of unmeasured
bias may be reflected in the hazard ratio estimate for calcium
channel blockers. Other hazard ratios can be compared with
calcium channel blockers (hazard ratio 0.95) rather than to a
hazard ratio of 1. We observed that the confidence intervals for
statins and diuretics did not contain 0.95, strengthening the case
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against them. The confidence interval for β blockers did contain
0.95 and is therefore not convincingly different from our
metabolically neutral control.
The marginal results for the structural model are consistent with
a reduction in treatment selection bias, whereby higher risk
patients are more likely to receive treatment. The hazard ratios
from the unadjusted and baseline adjusted Cox models are
generally higher than those from the marginal structural model.
Interestingly, the baseline adjusted Cox model provides nearly
identical results to that of the unadjusted model. This likely
reflects the fact that the population was treatment naïve at
baseline and post-baseline factors play a role in post-baseline
treatment use. This emphasises the important role of adjustment
for post-baseline factors.
Strengths and limitations of this study
Our study has three major strengths compared with previous
studies. Firstly, our study is large; the largest of its kind to date.
Secondly, our study used standard methods for diagnosing
diabetes, with prespecified serial glucose assessments and
laboratory confirmation for all patients, whereas other studies
have relied on billing data8 or pooled results data in
meta-analyses.6 7 Thirdly, we began with a treatment naïve
population and used marginal structural models to account for
the time varying confounders for the use of drug therapy and
its association with new onset diabetes. This allowed
pseudorandomisation of treatment strategies in which, at each
visit, patients who had not yet progressed to diabetes were
re-examined for use of the drugs of interest according to their
full covariate history. By only including a treatment naïve
population, we estimated the effect of first time initiation of
drugs on new onset diabetes.
Firstly, this was a reanalysis of a clinical trial that was not
prospectively designed to examine the association between new
onset diabetes and β blocker, statin, and diuretic use. Biases
due to the observational nature of treatment assignment are
possible. Documentation of the reason for initiation of new
non-trial study treatment was not collected as part of the trial
protocol. Although the NAVIGATOR dataset captured strong
predictors of new onset diabetes and all known factors expected
to be associated with treatment use, these measured confounders
were not measured perfectly. For example, glucose tolerance
and blood pressure are known to be measured with error, which
could lead to imperfect adjustment. The interval nature of data
collection implied that covariates could only be updated to their
most recent value, six months before treatment decisions, but
not immediately before. Given the potential for residual
treatment selection bias, we emphasised the comparison with
calcium channel blocker. Secondly, we were unable to examine
the effects of treatment stratified by duration of drug use—that
is, we did not explore differential effects according to the
duration of use but estimated the effect averaged over duration.
Because we did not collect information on dosage or category,
we cannot determine whether there was a dose or category
response for these drugs, especially when previous studies have
showed that diuretic and β blocker effect can vary within these
classes of drugs, and intensive dose (versus lower dose) statins
may be associated with an increased risk of new onset diabetes.7
Thirdly, we fit proportional hazards models and did not attempt
to investigate time varying effects of treatment, as a more
complex model would have trade-offs in precision and
interpretability. Finally, we did not examine the effect of new
onset diabetes on cardiovascular disease outcomes, so we cannot
determine the effect of increased rate of diabetes on major
outcomes in this population at high risk for cardiovascular
disease.
Conclusions
We found that in high risk patients with impaired glucose
tolerance and established cardiac risk factors, statins and
diuretics increased the risk of new onset diabetes. Our findings
suggest that glycaemia should be better monitored when these
drugs are initiated in high risk patients. However, these findings
should be confirmed in subsequent studies where those agents
are prospectively prescribed in a randomised manner among
patients at high risk of diabetes.
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What is already known on this topic
β blockers and diuretics may increase the risk of new onset diabetes
Recent evidence suggests that statins also increase this risk
The degree to which use of these drugs in patients with impaired glucose tolerance and other cardiovascular risk factors is associated
with new onset diabetes is unknown
What this study adds
Among people with impaired glucose tolerance and other cardiovascular risk factors and with serial glucose measurements, diuretics
and statins were associated with an increased risk of new onset diabetes
The effect of β blockers was, however, indeterminate
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Tables
Table 1| Follow-up of time dependent confounders
Frequency of measurementTreatment*Variables
Vital signs:
Every 6 monthsCalcium channel blockers, β blockers,
diuretics
Systolic blood pressure
Calcium channel blockers, β blockers,
diuretics
Diastolic blood pressure
β blockersHeart rate
StatinsSmoking status
StatinsBody mass index
Covarying events:
Every 6 monthsStatins, β blockersCardiovascular endpoint: myocardial infarction, coronary
revascularisation, and hospital admission for unstable angina
β blockersAtrial fibrillation
Diuretics, β blockersCongestive heart failure
StatinsPeripheral revascularisation
StatinsCerebrovascular disease: composite of stroke, transient ischaemic
attack, or carotid revascularisation
Laboratory tests:
Every 6 months for the first 3, every 12
months thereafter
†Fasting plasma glucose
Every 12 months†Oral glucose tolerance test
Baseline only†Glycated haemoglobin (HbA1C)
Baseline and 3 yearsStatinsLow and high density lipoprotein cholesterol
Every 12 monthsStatinsTriglycerides
Drugs:
Every 6 monthsStatins, β blockers, calcium channel blockers, and diuretics
*Drug thought to be indicated by or associated with corresponding variable.
†Variables not directly related to treatment initiation but highly associated with new onset diabetes.
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Table 2| Baseline characteristics of treatment naïve patients, by subsequent initiation. Values are median (25th, 75th centile), unless stated
otherwise
Calcium channel blocker (n=6294)Statin (n=6146)Diuretic (n=6346)β blocker (n=5640)
Characteristics No (n=5123)Yes (n=1171)No (n=4793)Yes (n=1353)No (n=5030)Yes (n=1316)No (n=4725)Yes (n=915)
62 (58, 68)64 (59, 69)63 (58, 68)63 (58, 68)62 (58, 68)64 (58, 69)63 (58, 68)64 (58, 69)Age (years)
51.951.256.051.045.650.052.650.6Female (%)
2.22.62.82.11.62.82.83.1Black (%)
65.386.883.576.665.685.369.180.0Hypertension (%)
3.83.93.62.81.63.12.03.3Congestive heart failure (%)
5.4 (4.7, 6.2)5.5 (4.7, 6.2)5.5 (4.8, 6.2)6.0 (5.3, 6.7)5.4 (4.7, 6.1)5.4 (4.7, 6.2)5.5 (4.8, 6.2)5.4 (4.7, 6.2)Total cholesterol (mmol/L)
5.36.01.43.06.45.02.84.5History of CABG (%)
14.817.110.613.016.817.48.815.3History of angina (%)
6.1 (5.7, 6.4)6.1 (5.7, 6.4)6.1 (5.7, 6.4)6.0 (5.7, 6.4)6.1 (5.7, 6.4)6.0 (5.7, 6.4)6.1 (5.7, 6.4)6.0 (5.7, 6.4)Fasting glucose (mmol/L)
5.8 (5.5, 6.1)5.8 (5.6, 6.1)5.8 (5.5, 6.1)5.8 (5.5, 6.1)5.8 (5.5, 6.1)5.8 (5.5, 6.1)5.8 (5.5, 6.1)5.8 (5.5, 6.1)HbA1c (%)
CABG=coronary artery bypass graft surgery; HbA1c=glycated haemoglobin A1c.
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Table 3| Effect of time dependent drugs on progression to diabetes
Absolute excess risk† (95% CI)
at 5 years (%)
MSM adjusted† hazard ratio
(95% CI)
Baseline adjusted* hazard ratio
(95% CI)
Unadjusted hazard ratio (95%
CI)Drugs
2.6 (−2.3 to 8.0)1.10 (0.92 to 1.31)1.23 (1.05 to 1.44)1.25 (1.07 to 1.46)β blocker
5.9 (1.5 to 10.7)1.23 (1.06 to 1.44)1.36 (1.19 to 1.55)1.36 (1.20 to 1.55)Diuretics
8.1 (3.5 to 13.0)1.32 (1.14 to 1.48)1.30 (1.13 to 1.49)1.30 (1.14 to 1.48)Statins
−1.5 (−5.8 to 3.4)0.95 (0.79 to 1.13)0.98 (0.84 to 1.14)1.01 (0.87 to 1.18)Calcium channel blocker
MSM=marginal structural model.
*Standard Cox proportional hazard model with regression adjustment for baseline variables, and treatment included as a time dependent covariate.
†MSM with regression adjustment for baseline variables and inverse probability of treatment weighting for time dependent confounders; truncation of extreme
weights applied at 0.25th centile and 99.75th centile.
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Figure
Patients enrolled in NAVIGATOR trial and their use of drugs of interest at baseline. CCB=calcium channel blocker. Cohorts
are not mutually exclusive but may receive other drugs
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